Milestones

1998
The active ingredient dronabinol is the only cannabinoid marketable in Germany and can be prescribed as a narcotic.
Ill. Molecules
2000
THC Pharm offers synthetically produced dronabinol in Germany as an active ingredient.
Ill. Microscope
2002
Bionorica Ethics begins offering naturally prepared dronabinol from cannabis plants.
Ill. Cannabis plant
2007
Integrated production technology with AGES (Austrian Agency for Health and Food Safety Ltd.) from the plant to the final substance.
Ill. Cannabis flower
2013
THC pharm starts with the CBD production.
Ill. CBD production
2014
THC Pharm and Bionorica ethics are merged under the Cannabinoid Compound Company – C³-Holding GmbH for short – to join forces in cannabinoid production, research and marketing.
Ill. C<sup>3</sup> logo
2018
Implementation of an additional purification step for the production of the high-purity active ingredient from natural cannabis flowers, a product unique in Germany.
Ill. THC raw
2018
The US regulatory agency FDA approves the first finished medicinal product with cannabidiol as a mono-active ingredient for the treatment of particularly severe, treatment-resistant forms of epilepsy. European licensing has also been applied for and is expected to be granted in 2019.
Ill. Logo FDA - The Food and Drug Administration

2018
Autumn 2018: Quadrupling of the production volume with a new high tech production plant in Neumarkt.
Ill. New high tech production